What is Rebiotix?
Rebiotix Inc., now a subsidiary of Ferring Pharmaceuticals, operates at the intersection of advanced microbiology and clinical medicine. The company specializes in the development of innovative microbiome-based therapies designed to treat debilitating diseases by restoring the natural balance of the human microbiome. By leveraging a sophisticated donor program and proprietary manufacturing processes, Rebiotix addresses significant unmet medical needs, positioning itself as a leader in the emerging field of live biotherapeutic products. Their market position is defined by a commitment to scientific excellence and a robust pipeline that bridges the gap between academic research and commercial-scale therapeutic delivery.
How much funding has Rebiotix raised?
Rebiotix has raised a total of $32.1M across 4 funding rounds:
Private Equity
$2.8M
Series A
$2.8M
Series B
$18M
Debt
$8.5M
Private Equity (2011): $2.8M, investors not publicly disclosed
Series A (2011): $2.8M led by Sofia Fund
Series B (2014): $18M, investors not publicly disclosed
Debt (2017): $8.5M, investors not publicly disclosed
Key Investors in Rebiotix
Sofia Fund
A venture capital firm focused on investing in women-led businesses and high-growth companies within the technology and healthcare sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Rebiotix?
Following its integration into the Ferring Pharmaceuticals ecosystem, the strategic focus for Rebiotix has shifted toward the global commercialization and regulatory approval of its lead candidates. The recent capital allocation provides the necessary runway to scale manufacturing capabilities and expand clinical trial infrastructure. Future growth will likely be driven by the expansion of their therapeutic portfolio and the optimization of their donor-derived product platform. As the medical community continues to recognize the therapeutic potential of the microbiome, Rebiotix is well-positioned to leverage its parent company's global distribution network to bring transformative treatments to patients worldwide, solidifying its status as a cornerstone of modern biopharmaceutical innovation.
See full Rebiotix company page
